GLP1R and hepatocellular carcinoma: The effect of exenatide on hepatic intracellular signaling was further evaluated, reaching a conclusion that GLP-1Rs could partake in hepatic insulin resistance, and that long-acting GLP-1R activators such as exenatide could be suitable candidates for the treatment of NASH and, consequently, NASH-related HCC.